Literature DB >> 26448593

History of surgical debridement, anticentromere antibody, and disease duration are associated with calcinosis in patients with systemic sclerosis.

M Mahmood1, J Wilkinson2, J Manning3, A L Herrick1.   

Abstract

OBJECTIVES: Systemic sclerosis (SSc)-related calcinosis is often painful and disabling. Our aim was to examine its clinical and serological associates, and whether it is possible to build a model to predict the presence of calcinosis.
METHOD: This was a retrospective cross-sectional study. Clinical and demographic variables examined were: age, gender, disease subtype, SSc duration, previous intravenous prostanoid infusions, surgical debridement and/or amputation, autoantibody status (anticentromere and antitopoisomerase), pulmonary fibrosis, and pulmonary hypertension. Univariable logistic regression was used to investigate associations between demographic and clinical factors and the odds of clinical calcinosis, then multivariable regression to obtain adjusted odds ratios (ORs) and confidence intervals (CIs).
RESULTS: A total of 317 patients (86% female, median age 60 years) were included: 94 (30%) had clinically apparent calcinosis. Age and gender were similar in those with and without calcinosis. Only surgical debridement (OR 3.55, 95% CI 1.71-7.53), anticentromere status (OR 2.32, 95% CI 1.27-4.32), and disease duration (OR 1.08, 95% CI 1.04-1.11) remained significant predictors after adjusting for other variables. In combination, the selected variables explained approximately 18% of the variation in the outcome but did not grant sufficient predictive power to discriminate between those with and without calcinosis [Nagelkerke's R(2) = 0.18, area under the receiver operating characteristic curve (AuROC) = 0.51, both adjusted for optimism].
CONCLUSIONS: History of surgical debridement, positive anticentromere antibody, and disease duration were independently associated with calcinosis. However, the low explanatory and discriminatory power of a multiple logistic regression model suggests there are other important predictors of calcinosis unaccounted for in this analysis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26448593     DOI: 10.3109/03009742.2015.1086432

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  3 in total

Review 1.  Subcutaneous calcinosis: Is it different between systemic sclerosis and dermatomyositis?

Authors:  Antonia Valenzuela; Lorinda Chung
Journal:  J Scleroderma Relat Disord       Date:  2021-10-28

2.  The impact of skin calcinosis on digital ulcers in patients with SSc: clinical and prognostic stratification using the "wound bed score".

Authors:  Simone Barsotti; Valentina Venturini; Marco Di Battista; Agata Janowska; Valentina Dini; Alessandra Della Rossa; Marta Mosca
Journal:  Int Wound J       Date:  2020-09-14       Impact factor: 3.315

3.  Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis.

Authors:  Antonia Valenzuela; Murray Baron; Tatiana S Rodriguez-Reyna; Susanna Proudman; Dinesh Khanna; Amber Young; Monique Hinchcliff; Virginia Steen; Jessica Gordon; Vivien Hsu; Flavia V Castelino; Sara Schoenfeld; Shufeng Li; Joy Y Wu; David Fiorentino; Lorinda Chung
Journal:  Semin Arthritis Rheum       Date:  2020-06-17       Impact factor: 5.532

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.